Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.

Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS.

Breast Cancer Res. 2018 Jul 5;20(1):67. doi: 10.1186/s13058-018-0993-z.

2.

The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.

Zacharopoulou N, Tsapara A, Kallergi G, Schmid E, Alkahtani S, Alarifi S, Tsichlis PN, Kampranis SC, Stournaras C.

Cell Physiol Biochem. 2018;47(1):368-377. doi: 10.1159/000489917. Epub 2018 May 14.

3.

The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.

Zacharopoulou N, Tsapara A, Kallergi G, Schmid E, Tsichlis PN, Kampranis SC, Stournaras C.

Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):587-597. doi: 10.1016/j.bbamcr.2018.01.009. Epub 2018 Feb 2.

PMID:
29408056
4.

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.

Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A.

Ther Adv Med Oncol. 2018 Jan 15;10:1758834017750121. doi: 10.1177/1758834017750121. eCollection 2018.

5.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

6.

Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.

Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S.

Mol Oncol. 2018 Jan;12(1):21-32. doi: 10.1002/1878-0261.12114. Epub 2017 Nov 16.

7.

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.

Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, Souglakos J, Georgoulias V.

PLoS One. 2017 Jul 18;12(7):e0181211. doi: 10.1371/journal.pone.0181211. eCollection 2017.

8.

Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells.

Stagno MJ, Zacharopoulou N, Bochem J, Tsapara A, Pelzl L, Al-Maghout T, Kallergi G, Alkahtani S, Alevizopoulos K, Dimas K, Calogeropoulou T, Warmann SW, Lang F, Schmid E, Stournaras C.

Cell Physiol Biochem. 2017;42(4):1366-1376. doi: 10.1159/000479200. Epub 2017 Jul 14.

9.

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.

Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G.

Oncotarget. 2017 Jan 17;8(3):5309-5322. doi: 10.18632/oncotarget.14144.

10.

Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs).

Kallergi G, Politaki E, Alkahtani S, Stournaras C, Georgoulias V.

Cell Physiol Biochem. 2016;40(3-4):411-419. Epub 2016 Nov 25.

11.

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2015 Aug 19;17:113. doi: 10.1186/s13058-015-0624-x.

12.

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.

Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V.

PLoS One. 2015 Jun 17;10(6):e0123683. doi: 10.1371/journal.pone.0123683. eCollection 2015.

13.

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.

Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulias V, Agelaki S.

Breast Cancer Res. 2014 Nov 29;16(6):485. doi: 10.1186/s13058-014-0485-8.

14.

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.

Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S.

BMC Cancer. 2014 Sep 3;14:651. doi: 10.1186/1471-2407-14-651.

15.

Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.

Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2014 Apr;73(4):685-93. doi: 10.1007/s00280-014-2387-y. Epub 2014 Feb 4.

PMID:
24493157
16.

Apoptotic circulating tumor cells in early and metastatic breast cancer patients.

Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, Georgoulias V, Agelaki S.

Mol Cancer Ther. 2013 Sep;12(9):1886-95. doi: 10.1158/1535-7163.MCT-12-1167. Epub 2013 Jun 18.

17.

Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.

Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES.

Mol Cancer Res. 2013 Oct;11(10):1248-57. doi: 10.1158/1541-7786.MCR-13-0096. Epub 2013 Jun 6.

18.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D.

Ann Oncol. 2012 Jul;23(7):1744-50. doi: 10.1093/annonc/mds020. Epub 2012 Feb 29.

PMID:
22377561
19.

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.

Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D.

Breast Cancer Res. 2011 Jun 10;13(3):R60. doi: 10.1186/bcr2897.

20.

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S.

Breast Cancer Res. 2011 Jun 10;13(3):R59. doi: 10.1186/bcr2896.

Supplemental Content

Loading ...
Support Center